Medical Updates

Medical News

May 26, 2020 - OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)(1)

September 7, 2016 - Phase 2 results for PA101 show 30% decrease for IPF patients with Refractory Chronic Cough

Refractory = stubborn or unmanageable
Chronic = lasting 3 months or more
Cough = A rapid expulsion of air from the lungs, typically in order to clear the lung airways of fluids, mucus, or other material. Also known as tussis.

In addition to the PF/IPF itself, certain conditions such as asthma, gastroesophageal reflux disease, obstructive sleep apnea, angiotensin-converting enzyme inhibitor use, eosinophilic bronchitis, and rhinosinusitis may cause chronic refractory cough. Research is finally turning its attention to symptom management as Quality of Life (QOL) and well as life expectancy.  Cough in idiopathic pulmonary fibrosis

The Treatment of Refractory Chronic Cough With PA101 (NCT02412020), a clinical trial for IPF that was done at sites in the UK and Netherlands was completed and results released by the trial sponsor Patara Pharma. The Phase 2 study was with 24 adult IPF patients daytime average cough count ≥15 per hour at screening.

Presented at the recent European Respiratory Society International Congress in London, the findings showed that treatment with PA101 reduced frequency of daytime cough by 30 percent with no major side effects and reported to be well-tolerated. The company plans a Phase 2b study to determine the optimal dosage.

PA101 (sodium cromoglicate) is a late-stage immune modulator with mast cell stabilizing properties that is delivered directly to the lungs via the company’s proprietary investigational PARI eFlow nebulizer system.

An investigational drug generally requires a successful Phase 3 trial before an application is made to approve the drug.  Once approved the drug can be used for clinical application.  In the meantime, CPFF continues to follow emerging research. 

Read More                Patara Pharma Press Release

September 14, 2015 - Striking gold in delivering drugs for injured lungs

A novel tiny gold particle has been developed by Toronto General Research Institute (TGRI) scientists that can penetrate cell membranes to deliver drugs directly into cell targets. Read More

August 28, 2015 - New U of T-designed Microchip Predicts Viability of Donor Lungs

University of Toronto researchers have found a way to quickly determine if a donor lung is suitable for transplant by using a microchip to measure biomarkers. Read More

July 31, 2015 - HeadStart™ Patient Assistance Program now available for OFEV™ patients

OFEV™ (nintedanib) is an anti-fibrotic/anti-inflammatory agent now approved by Health Canada for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. The HeadStart™ Patient Assistance Program is now in place to assist patients who have been prescribed OFEV™. Read more.

July 16, 2015 – Treatment of Idiopathic Pulmonary Fibrosis

An Update of the 2011 Clinical Practice Guideline from the American Thoracic Society. This document updates the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/
Latin American Thoracic Association guideline on idiopathic pulmonary fibrosis treatment. Read the complete executive summary.

September 3, 2014 – CPFF News Release: Ontario to fund Esbriet

Ontarians affected by idiopathic pulmonary fibrosis (IPF) – a rare, progressive and fatal lung disease – have finally been given the chance to breathe after an emotional rollercoaster ride lasting almost two years, as they fought for access to the first available treatment for their deadly disease.  Read the complete news release.

Go to News regarding Esbriet to read about the Ontario criteria and to keep informed about announcements for other provinces and territories.

July 17, 2014 - FDA grants Breakthrough Therapy Designation for 2 IPF drugs

FDA grants Breakthrough Therapy Designation to both Nintedanib and Esbriet (Pirfenidone). For more information, Boehringer Ingelheim and InterMune press releases and FDA Frequently Asked Questions: Breakthrough Therapies

Medical Conference Updates

ERS 2014 (European Respiratory Society Annual Congress)

ERS 2014 was held in Munich from September 6-10.
Articles from Script Medical Reporter
The following articles were compiled by a medical reporter from Script Medical that was on the ground during ATS 2014.

When should IPF treatment be initiated

Genetic susceptibility to IPF

Addressing depression and anxiety in IPF

Promising long-term safety of Esbriet (pirfenidone)

ICLAF 2014 (International Colloquium on Lung and Airway Fibrosis)

Extremely excited, enthusiastic and hopeful would be the best way to describe our anticipation for the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) held in Mont Tremblant, Quebec this past September 20 – 24, 2014….. And, we weren’t disappointed.
Read more about Team CPFF at ICLAF

ICLAF 2014 Brings Hope to IPF patients worldwide

DSC_1680Extremely excited, enthusiastic and hopeful would be the best way to describe our anticipation for the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) held in Mont Tremblant, Quebec this past September 20 – 24, 2014….. And, we weren’t disappointed.

It was a privilege to be among these world leading scientists and clinicians committed to enhancing and improving research in fibrosis and to improve care of patients with IPF.DSC_1738

ICLAF was established in 1980, and according to the meeting program, 2014 is one of the most exciting years ever for the IPF community and the patients. We have seen the results and impact of several crucial Phase 3 trials in May, which will hopefully result in DSC_1852worldwide approval and access to desperately needed IPF drugs sooner than later. While these drugs do not cure the disease they do slow it down giving patients more time for other treatments to come along and, eventually, a cure. ICLAF brings together international leaders, scientists, clinicians, fellows, students and patient advocates in a relaxed and friendly atmosphere.CPFbanner

This was the first ICLAF event to include patient groups.  We made submissions to the attendees and I was pleased to see that our presentation was very well received.  These scientists are listening to us.

DSC_1736This year’s meeting brought together 350 attendees from 19 countries presenting and defending 130 abstracts (research papers) in both basic and clinical science; it was the largest ICLAF ever. The meeting program alone was an incredible 167 pages.

What does this mean for people living with IPF and their caregivers?  It means HOPE, hope that these great scientific minds who have turned their attention to our horrendous disease are working together to better understand the DSC_2002disease and to create more innovative solutions to treat IPF! Watch the CPFF website for regular updates about treatments and clinical trial updates.DSC_2003

When you see these people gathering together and collaborating as they did you KNOW they will find a cure.

For our part, the CPFF is a proud Silver sponsor of ICLAF 2014 following our initial sponsorship of ICLAF 2012. We were able to set up our booth, meet scientists and peers DSC_1664from around the world, share our educational materials and information about our campaigns to help those assembled find ways DSC_1704to promote awareness in their countries. Best of all we spoke to them at length about who we are as patients.

Our most recent campaign, Kiss IPF
Goodbye (#kissIPFgoodbye) generated a tremendous amount of excitement. Currently, we are in discussion with other countries about making #kissIPFgoodbye a global campaign –stay tuned!!!DSC_1669






View more photos.

Robert Davidson

ATS 2014 (American Thoracic Society International Conference)

ATS 2014 was held in San Diego from May 16-21. Exciting news as it happened was reported here from ATS 2014 including some post conference articles from a medical reporter who was on the ground at the conference.

Post Conference Reviews for Results Reported at ATS 2014
CPFF Conference Call — ASCEND Overview with Dr. Martin Kolb, Firestone Institute for Respiratory Health, St. Joseph’s Healthcare


Ask A Doc Clinical Trial Update Webinar – Pulmonary Fibrosis Foundation

Articles from Script Medical Reporter